Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1

Conditions

ENSAT Stage I Adrenal Cortex Carcinoma 1Adrenocortical Carcinoma 1

Interventions

pembrolizumab 602Cyclophosphamide 545Magnetic Resonance Spectroscopy 524Radiotherapy 513Specimen Handling 506Nivolumab 412Cisplatin 380Carboplatin 368Biopsy 306Blood Specimen Collection 302Radiosurgery 290Paclitaxel 280Surveys and Questionnaires 270Gemcitabine 270Standard of Care 267Drug Therapy 263Dexamethasone 263fludarabine 262Bevacizumab 253venetoclax 251Oxaliplatin 209Capecitabine 201Rituximab 198Radiation 192Fluorouracil 189Ipilimumab 188durvalumab 184Doxorubicin 179Etoposide 176atezolizumab 175

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Mitotane × 1 year × Clear all
NCT03583710 2026-04-07

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

M.D. Anderson Cancer Center

Phase 3 Recruiting
240 enrolled

ENSAT Stage I Adrenal Cortex Carcinoma

NCT05634577 2025-06-19

A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡